Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +51.68%
#2 TENDIES TENDIES +48.99%
#3 Pons Pons +46.31%
#4 PondCoin PondCoin +46.06%
#5 Magma Finance Magma Finance +33.33%
#6 StonkBroker StonkBroker +31.47%
#7 Purr Purr +29.09%
#8 Ocean Protocol Ocean Protocol +27.74%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 Starpower Starpower +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Rang in Aktien #29319
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Aktienkurs
$0.62008105
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$21.81M
Veränderung (1 Tag)
0.26%
Veränderung (1 Jahr)
-31.95%
Land
TW
Handel SynCore Biotechnology Co.,Ltd (4192)

Kategorie

Healthcare
Gewinn für SynCore Biotechnology Co.,Ltd (4192)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von SynCore Biotechnology Co.,Ltd betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von SynCore Biotechnology Co.,Ltd von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH